Paula M Keith

US Patent:

6783939, Aug 31, 2004

Filed:

Nov 16, 2001

Appl. No.:

09/991258

Inventors:

Robert Olmsted - Chapel Hill NC
Paula Keith - Holly Springs NC
Sergey Dryga - Chapel Hill NC
Ian Caley - Durham NC
Maureen Maughan - Durham NC
Robert Johnston - Chapel Hill NC
Nancy Davis - Chapel Hill NC
Ronald Swanstrom - Chapel HIll NC

Assignee:

Alphavax, Inc. - Research Triangle Park NC
University of North Carolina at Chapel Hill - Chapel Hill NC

International Classification:

C12Q 168

US Classification:

435 6, 435 5, 435 697, 4353391, 4353201, 536 231, 536 2372, 4241921, 4242081

Abstract:

The present invention provides methods and compositions comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from 1) an isolated nucleic acid encoding an env gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a gg gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the gg gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the gg gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a pol gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the pol gene product or immunogenic fragment thereof is modified to inhibit protease, integrase, RNase H and/or reverse transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle.

US Patent:

20050123555, Jun 9, 2005

Filed:

Aug 30, 2004

Appl. No.:

10/929234

Inventors:

Robert Olmsted - Chapel Hills NC, US
Paula Keith - Holly Springs NC, US
Sergey Dryga - Chapel Hill NC, US
Ian Caley - Durham NC, US
Maureen Maughan - Durham NC, US
Robert Johnston - Chapel Hill NC, US
Nancy Davis - Chapel Hill NC, US
Ronald Swanstrom - Chapel Hill NC, US

International Classification:

C12Q001/68
A61K039/29
C07H021/02
C12N015/86
C12N007/00

US Classification:

424189100, 435456000, 435235100, 435325000, 536023720

Abstract:

The present invention provides methods and compositions comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from 1) an isolated nucleic acid encoding an env gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a gag gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the gag gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the gag gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a pol gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the pol gene product or immunogenic fragment thereof is modified to inhibit protease, integrase, RNase H and/or reverse transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle.

US Patent:

51047969, Apr 14, 1992

Filed:

Apr 6, 1987

Appl. No.:

7/034847

Inventors:

Paula M. Keith - Terre Haute IN
Wendy Cain - Terre Haute IN

Assignee:

International Minerals & Chemical Corp. - Northbrook IL

International Classification:

C12P 2102
C07K 1300
C12N 121
C12N 1503
C12N 1518

US Classification:

435 694

Abstract:

A high titer fermentation process using transformed Escherichia coli cells carrying a plasmid containing DNA which codes for Somatomedin C is disclosed. Titers of about 900-1000 mg/L have been obtained using the method of the present invention; about two times the titer of prior art processes.

US Patent:

47627840, Aug 9, 1988

Filed:

Jul 15, 1985

Appl. No.:

6/754578

Inventors:

Paula M. Keith - West Terre Haute IN
Wendy J. Cain - Terre Haute IN

Assignee:

International Minerals & Chemical Corp. - IN

International Classification:

C12P 2102
C12N 1500

US Classification:

435 70

Abstract:

A high density fermentation process for high yield production of bovine growth hormone by transformant E. coli is described. The process employs transformant strains of E. coli containing an expression vector coding for bovine growth hormone under the control of a bacteriophage lambda promoter-operator and a plasmid containing the. lambda. cI857 gene which codes for the temperature-sensitive repressor protein. In the initial growth period, the level of dissolved oxygen in the fermentation medium is maintained at about 20% to 60% saturation and the temperature of the medium is kept at 26. degree. -30. degree. C. Production of bovine growth hormone is then induced by raising the temperature of the medium to at least about 42. degree. C. The temperature is then reduced to about 38. degree. C. to 41. degree. C. to optimize cell growth for the remainder of the induction period, during which the level of dissolved oxygen in the medium is maintained at about 10% to 40% saturation.